Canadian Cancer Trials Group Bulletins

General


Results of Canadian Cancer Trials Group PR.7 Presented at ASCO

As we reported in the previous edition of the Canadian Cancer Trials Group Bulletin, three trials led by the Canadian Cancer Trials Group were chosen as "Best of ASCO" -- MA.20, MAP.3, and PR.7.

Results from Canadian Cancer Trials Group PR.7 show that men with prostate cancer who are treated with intermittent courses of androgen-suppressing therapy will live as long as those receiving continuous therapy.

These results were presented by the trial co-chair, Dr. Juanita Crook from the BC Cancer Agency in Kelowna, during the American Society of Clinical Oncology Annual Meeting in Chicago on Monday, June 6. Dr. Crook co-led PR.7 with Dr. Laurence Klotz from the Odette Cancer Centre at Sunnybrook Health Sciences Centre in Toronto.

The Canadian Cancer Society has highlighted these results ... http://www.cancer.ca/Canada-wide/About%20us/Media%20centre/CW-Media%20releases/CW-2011/CCS%20research%20best%20of%20best%20at%20ASCO.aspx?sc_lang=en.